Risperidone

Generic Name
Risperidone
Brand Names
Perseris, Risperdal, Rykindo, Uzedy, Okedi
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
106266-06-2
Unique Ingredient Identifier
L6UH7ZF8HC
Background

Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication

Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions
Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
Associated Therapies
-
Clinical Trials
Related News

Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder

Not Applicable
Completed
Conditions
Schizotypal Personality Disorder
Interventions
Drug: Risperidone
Drug: Placebo
First Posted Date
2005-09-12
Last Posted Date
2016-08-04
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
25
Registration Number
NCT00158028
Locations
🇺🇸

Bronx VA, Bronx, New York, United States

Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)

Phase 1
Completed
Conditions
Child Development Disorders, Pervasive
First Posted Date
2005-09-07
Last Posted Date
2012-10-29
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
100
Registration Number
NCT00147394
Locations
🇺🇸

Children's Hospital of Michigan/Wayne State University, Detroit, Michigan, United States

🇺🇸

Cincinnati Children's Hospital, Cincinnati, Ohio, United States

🇺🇸

Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States

and more 2 locations

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

Phase 4
Completed
Conditions
Anorexia Nervosa
Interventions
Drug: Placebo
Drug: Risperidone
First Posted Date
2005-09-01
Last Posted Date
2016-02-02
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
41
Registration Number
NCT00140426
Locations
🇺🇸

The Children's Hospital, Denver, Colorado, United States

The Effects of Risperidone and Olanzapine on Thinking

Phase 4
Completed
Conditions
Schizophrenia
Psychotic Disorders
First Posted Date
2005-04-15
Last Posted Date
2009-01-21
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00108368
Locations
🇺🇸

VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder

First Posted Date
2004-12-22
Last Posted Date
2014-08-22
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
296
Registration Number
NCT00099983
Locations
🇺🇸

VA Medical Center, Tuscaloosa, Tuscaloosa, Alabama, United States

🇺🇸

VA Connecticut Health Care System (West Haven), West Haven, Connecticut, United States

🇺🇸

VA Greater Los Angeles Healthcare System, West LA, West Los Angeles, California, United States

and more 17 locations

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Phase 3
Completed
Conditions
Major Depressive Disorder
First Posted Date
2004-11-01
Last Posted Date
2011-12-06
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
630
Registration Number
NCT00095134
Locations
🇺🇸

Southwestern Research Institute, Burbank, California, United States

🇺🇸

Southwest Biomedical Research Foundation, Tucson, Arizona, United States

🇺🇸

nTouch Research - Peoria, Peoria, Illinois, United States

and more 66 locations

Investigate Risperidone for the Treatment of Schizophrenia in Adolescents

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2004-07-21
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
160
Registration Number
NCT00088075

RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

First Posted Date
2004-03-25
Last Posted Date
2013-08-16
Lead Sponsor
Yale University
Target Recruit Count
124
Registration Number
NCT00080145
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents

Phase 3
Completed
Conditions
Bipolar Disorder
First Posted Date
2004-01-16
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
13
Registration Number
NCT00076115

Treating Behavioral Disturbances in Individuals With Dementia

Phase 2
Completed
Conditions
Dementia
First Posted Date
2003-12-03
Last Posted Date
2014-03-10
Lead Sponsor
University of Pittsburgh
Target Recruit Count
137
Registration Number
NCT00073658
Locations
🇺🇸

University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy